In order to acquire the main competitor to its key commercial product, Questcor Pharmaceuticals has outbid Retrophin to acquire rights to Synacthen® (tetracosactide) and Synacthen Depot® in more than three dozen international markets, including the US, from Novartis in a deal worth at least US$135 M. Synacthen, which has yet to be approved in the US, is a synthetic fragment of adrenocorticotropic hormone, the active ingredient in Questcor’s H.P Acthar® Gel, which has been approved by the US FDA for 19 indications that have an inflammatory component.